Akebia Therapeutics Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
-
-
1,535.00
177,984.00
207,742
Cost of Goods Sold (COGS) incl. D&A
1.30
49.00
96.00
-
-
8,667
Gross Income
1.30
49.00
96.00
-
-
199,075
SG&A Expense
15,931.90
37,448.50
61,117.00
137,199.00
257,284.00
354,136
EBIT
15,933.20
37,497.50
61,213.00
135,960.00
79,917.00
155,061
Unusual Expense
2,419.80
442.50
300.00
500.00
-
23,100
Non Operating Income/Expense
1,049.80
700.00
287.00
188.00
204.00
81
Interest Expense
703.60
-
-
-
-
-
Pretax Income
13,167.20
37,034.00
60,716.00
135,747.00
76,914.00
171,926
Consolidated Net Income
13,167.20
37,034.00
60,716.00
135,747.00
76,914.00
143,588
Net Income
13,167.20
37,034.00
60,716.00
135,747.00
76,914.00
143,588
Net Income After Extraordinaries
13,167.20
37,034.00
60,716.00
135,747.00
76,914.00
143,588
Net Income Available to Common
69,053.00
123,933.00
60,716.00
135,747.00
76,914.00
143,588
EPS (Basic)
3.43
8.04
2.29
3.60
1.77
2.47
Basic Shares Outstanding
20,147.70
15,406.40
26,469.20
37,716.90
43,500.80
58,038.30
EPS (Diluted)
3.43
8.04
2.29
3.60
1.77
2.47
Diluted Shares Outstanding
20,147.70
15,406.40
26,469.20
37,716.90
43,500.80
58,038.30
EBITDA
15,931.90
37,448.50
61,117.00
135,664.00
79,300.00
152,645
Non-Operating Interest Income
-
206.00
510.00
901.00
2,799.00
6,154
Preferred Dividends
55,885.80
86,899.00
-
-
-
-
About Akebia Therapeutics
View Profile
